NovaBridge Biosciences (NBP) Receivables - Accured (2018 - 2025)

NovaBridge Biosciences (NBP) posted quarterly Receivables - Accured of $5000.0 for Q4 2025, down 99.52% year-on-year from $1.0 million in Q4 2024, and down 83.33% on a QoQ basis from $30000.0 in Q3 2025.

NovaBridge Biosciences (NBP) Receivables - Accured (2018 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Receivables - Accured for 5 consecutive years, with $5000.0 the latest figure, recorded in Q4 2025.

  • Quarterly Receivables - Accured fell 99.52% year-over-year to $5000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5000.0 (down 99.52% YoY) and the FY2025 annual result came in at $5000.0, down 99.52% from the prior year.
  • Receivables - Accured retreated to $5000.0 in Q4 2025 per NBP's latest filing, from $30000.0 in the prior quarter.
  • Over the last five years, Receivables - Accured for NBP reached as high as $1.0 million in Q4 2024 and fell as low as $5000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables - Accured (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 NovaBridge Biosciences 389.86 Mn 389.86 Mn - 5,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 5,000.00
Dec 31, 2025 5,000.00
Sep 30, 2025 30,000.00
Sep 30, 2025 30,000.00
Jun 30, 2025 28,000.00
Jun 30, 2025 28,000.00
Dec 31, 2024 1.04 Mn
Dec 31, 2024 1.04 Mn
Dec 31, 2020 35,610.82
Dec 31, 2020 35,610.82
Dec 31, 2019 108,396.91
Dec 31, 2019 108,396.91
Dec 31, 2018 217,233.64
Dec 31, 2018 217,233.64